Onco Actu du 25 janvier 2016

	3.1 Tabac
E-cigarettes tied to reduced odds of quitting smoking [Reuters] "The odds of quitting were 28 percent lower for smokers using e-cigarettes than people not using e-cigarettes," said senior author Stanton Glantz, of the Center for Tobacco Control Research and Education at the University of California, San Francisco.
	4.2 Dép., diag. & prono. - Génome
Precision cancer treatment held back by low-quality biopsies [STAT] The MATCH trial, launched last August by the National Cancer Institute, is billed as “the largest, most scientifically rigorous precision medicine cancer trial to date.”
	4.5 Dép., diag. & prono. - Colorectal
1 in 7 colorectal cancer patients diagnosed before recommended screening age [University of Michigan Health System] Should guidelines change to begin screening at an earlier age? Hendren says not so fast. “This would be a big and costly change, and I don’t know whether it would help more people than it would hurt,” she says.
Colonoscopy at 40? Study finds a possible benefit [STAT] For their study, Hendren and her colleagues studied nearly 40,000 colorectal cancer patients whose average age at diagnosis was 42 and compared them to older patients.
Screening gets top marks for picking up bowel cancer early [Cancer Research UK] For the first time, data shows the stage (one to four) at which cancer is detected by the different routes to diagnosis – through screening, by a GP referral**, or as an emergency.
	5. Traitements
NHS fast-tracks drug docetaxel for advanced prostate cancer patients [The Guardian] The announcement scraps the previous guidelines that patients had to wait for the chemotherapy drug docetaxel until existing hormone-based treatments had stopped working.
	5.2 Pharma
OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer [oncoGenex] Data from the Phase 2 Spruce™ trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.
	5.2.3 Pharma - économie
Heat Biologics Seeks More Cash for Bladder Cancer Immunotherapy Push [Xconomy] Heat aims to trigger that immune response by introducing antigens that share the characteristics of cancer cells. The company calls its platform technology Immune Pan-Antigen Cytotoxic Therapy, or “ImPACT.”
	5.3 Traitements - FDA, EMA,...
Pfizer's Ibrance on track for UK early access scheme [Pharma Times] Pfizer UK’s Ibrance (palbociclib) has cleared the first hurdle to joining the UK’s Early Access to Medicines Scheme after being awarded ‘Promising Innovative Medicine’ status by the Medicines and Healthcare Regulatory Agency.
	5.3.4 Traitements - AMM (FDA, EMA)
FDA approves new Kyprolis combo for multiple myeloma [Pharmafile] The latest green-light means that Kyprolis (carfilzomib) injection can be used in the US in combination with dexamethasone, or with Celgene’s Revlimid (lenalidomide) plus dexamethasone, to treat patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
FDA approves new uses for BMS’ Opdivo/Yervoy cancer combo [Pharmafile] This is the seventh approval for Opdivo in just over a year, and the fourth for late-stage melanoma.
Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status [BMS] FDA also expands use of Opdivo as single-agent to include previously untreated BRAF mutation-positive advanced melanoma patients, based on accelerated approval.
	5.4 Traitements - Economie
Patient groups funded by drugmakers are largely mum on high drug prices [USA Today] "It is worrisome because it is a conflict of interest even if you can’t prove it changes their position," says Ezekiel Emanuel, an oncologist and professor who chairs the University of Pennsylvania's department of medical ethics and health policy. "The patient voice carries a disproportionate amount of weight."
NY Governor Andrew Cuomo seeks to cap some drug prices [STAT] Under the proposal, which must be approved by the state legislature, the state health department would “develop a list of critical prescription drugs for which there is a significant public interest in ensuring rational pricing.”
NICE draft guidance recommends nivolumab for advanced skin cancer [NICE] The independent Committee decided that a consultation on the draft recommendations was not needed for this appraisal, so the recommendations could go straight to a final appraisal determination.
	5.5 ASCO
NewLink Genetics Presents Phase 1b Data of Indoximod in Combination With Gemcitabine/Nab-Paclitaxel for Patients With Metastatic Pancreatic Cancer That Show Encouraging Durable Responses With Delayed Pattern [NewLink Genetics] "The preliminary overall response rate is certainly promising, but I am particularly intrigued by the pattern of delayed and durable responses potentially suggesting an immune mediated mechanism of action," said Nathan Bahary, principal investigator of the study.
Adjuvant Therapy of Pancreas Cancer: Have We Raised The Bar? [Gastrointestinal Cancers Symposium] In conclusion, although gemcitabine is currently the standard of care, we are far from raising the bar, with disappointing 5-year survival rates of 10% to 30% in patients with resectable disease.
Optimizing Immunotherapy in Colorectal Cancer [Gastrointestinal Cancers Symposium] Much remains to be understood regarding the interplay between cytotoxics, biologics, immune therapies, and the tumor microenvironment, and the careful selection of target antigens to avoid collateral autoimmune toxicity.
Data Presented at ASCO GI Highlight the Feasibility of Second-Line Treatment in Patients with Metastatic Pancreatic Cancer Who Have Received First-Line Abraxane Plus Gemcitabine [Celgene] Multiple analyses examined ABRAXANE (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine followed by 5-FU-based regimens.
	6. Lutte contre les cancers
Women with high risk of cancer effectively told 'come back when you have tumours' [The Telegraph] Ms Pearce said she was shocked to discover that the company’s policies would not pay for preventive treatment – even if the odds that a patient would develop cancer were overwhelmingly stacked against her. “It seems cruel and ridiculous that they are effectively saying to me, ‘Come back when you have got cancer,’” she said.
	6.10 Politiques
Vice President Biden's cancer research initiative [National Cancer Institute] We are truly excited and fully prepared to work with researchers, advocates, patients, our partners in the private sector, and many others to achieve the Vice President’s vision. Douglas R. Lowy, M.D. - Acting Director, NCI.
	6.9 Controverses
Attack of the Research Parasites [In the Pipeline] The New England Journal of Medicine is taking a lot of shots for this editorial on the sharing of data.